A61K35/34

Exosomes and micro-ribonucleic acids for tissue regeneration

Several embodiments relate to methods of repairing and/or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and/or function.

Exosomes and micro-ribonucleic acids for tissue regeneration

Several embodiments relate to methods of repairing and/or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and/or function.

Exosomes and micro-ribonucleic acids for tissue regeneration

Several embodiments relate to methods of repairing and/or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and/or function.

DIFFERENTIATION-INDUCED CELL POPULATION FROM WHICH UNDIFFERENTIATED CELLS HAVE BEEN REMOVED, USE OF SAME, AND METHOD FOR PRODUCING SAME

Provided is a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less.

METHODS AND COMPOSITIONS TO MAINTAIN STEM CELL QUIESCENCE
20170335287 · 2017-11-23 ·

Compositions and methods are provided for induction and maintenance of quiescence of stem cells.

METHODS AND COMPOSITIONS TO MAINTAIN STEM CELL QUIESCENCE
20170335287 · 2017-11-23 ·

Compositions and methods are provided for induction and maintenance of quiescence of stem cells.

Core-shell capsules for encapsulation of particles, colloids, and cells
11260080 · 2022-03-01 · ·

Methods for preparing capsules, such as micro- and/or nanocapsules from all-aqueous emulsions are described herein. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute with at least an optionally charged second phase containing a second solute. The solutes are incompatible with each other. The electrostatic forces between the two solutions induce the formation of droplets of a dispersed phase in a continuous phase. The droplets are then solidified to form the capsules.

Core-shell capsules for encapsulation of particles, colloids, and cells
11260080 · 2022-03-01 · ·

Methods for preparing capsules, such as micro- and/or nanocapsules from all-aqueous emulsions are described herein. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute with at least an optionally charged second phase containing a second solute. The solutes are incompatible with each other. The electrostatic forces between the two solutions induce the formation of droplets of a dispersed phase in a continuous phase. The droplets are then solidified to form the capsules.

STEM CELL DRUG FOR TREATING DIABETES

The use of a muscle stem cell in the preparation of a drug for preventing, alleviating and treating metabolic disorders, and a pharmaceutical composition for humans and animals, wherein the pharmaceutical composition comprises the muscle stem cell as a first active ingredient, a second active ingredient for regulating the glucose metabolism, and a pharmaceutically acceptable carrier.

STEM CELL DRUG FOR TREATING DIABETES

The use of a muscle stem cell in the preparation of a drug for preventing, alleviating and treating metabolic disorders, and a pharmaceutical composition for humans and animals, wherein the pharmaceutical composition comprises the muscle stem cell as a first active ingredient, a second active ingredient for regulating the glucose metabolism, and a pharmaceutically acceptable carrier.